Prevalence of Aspirin and Clopidogrel Resistance Among Patients With and Without Drug-Eluting Stent Thrombosis

American Journal of Cardiology

Volumn 104, Issue 4, 2009, Pages 525-530

  Pinto Slottow, Tina L ^a   Bonello, Laurent ^a   Gavini, Rekha ^a   Beauzile, Patricia ^a   Sushinsky, Steven J ^a   Scheinowitz, Mickey ^a   Kaneshige, Kimberly ^a   Xue, Zhenyi ^a   Torguson, Rebecca ^a   Tantry, Udaya ^b   Pichard, Augusto D ^a   Satler, Lowell F ^a   Suddath, William O ^a   Kent, Kenneth ^a   Gurbel, Paul ^b   Waksman, Ron ^a  

^a WASHINGTON HOSPITAL CENTER   (Colombia)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN; VASODILATOR AGENT;

ADULT; AGED; ARTICLE; BLOOD CLOTTING PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DRUG ELUTING STENT; FEMALE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; LOADING DRUG DOSE; MALE; POINT OF CARE TESTING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STENT THROMBOSIS;

AGED; ASPIRIN; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY THROMBOSIS; DRUG RESISTANCE; DRUG-ELUTING STENTS; FEMALE; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PREVALENCE; TICLOPIDINE;

EID: 67849117309     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.04.015     Document Type: Article

References (30)

1. Pinto Slottow T.L., Steinberg D.H., Roy P.K., Buch A.N., Okabe T., Xue Z., Kaneshige K., Torguson R., Lindsay J., Pichard A.D., Satler L.F., Suddath W.O., Kent K.M., and Waksman R. Observations and outcomes of definite and probable drug-eluting stent thrombosis seen at a single hospital in a four-year period. Am J Cardiol 102 (2008) 298-303
2. Kuchulakanti P.K., Chu W.W., Torguson R., Ohlmann P., Rha S.W., Clavijo L.C., Kim S.W., Bui A., Gevorkian N., Xue Z., Smith K., Fournadjieva J., Suddath W.O., Satler L.F., Pichard A.D., Kent K.M., and Waksman R. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation 113 (2006) 1108-1113
3. Leon M.B., Baim D.S., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K., Giambartolomei A., Diver D.J., Lasorda D.M., Williams D.O., Pocock S.J., Kuntz R.E., and Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339 (1998) 1665-1671
4. Gurbel P.A., Bliden K.P., Hiatt B.L., and O'Connor C.M. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
5. Lau W.C., Waskell L.A., Watkins P.B., Neer C.J., Horowitz K., Hopp A.S., Tait A.R., Carville D.G., Guyer K.E., and Bates E.R. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107 (2003) 32-37
6. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Catheter Cardiovasc Interv 71 (2008) E1-E40
7. Cutlip D.E., Baim D.S., Ho K.K., Popma J.J., Lansky A.J., Cohen D.J., Carrozza Jr. J.P., Chauhan M.S., Rodriguez O., and Kuntz R.E. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 103 (2001) 1967-1971
8. Iakovou I., Schmidt T., Bonizzoni E., Ge L., Sangiorgi G.M., Stankovic G., Airoldi F., Chieffo A., Montorfano M., Carlino M., Michev I., Corvaja N., Briguori C., Gerckens U., Grube E., and Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
9. Park D.W., Park S.W., Park K.H., Lee B.K., Kim Y.H., Lee C.W., Hong M.K., Kim J.J., and Park S.J. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 98 (2006) 352-356
10. Muller I., Besta F., Schulz C., Massberg S., Schonig A., and Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89 (2003) 783-787
11. Lev E.I., Patel R.T., Maresh K.J., Guthikonda S., Granada J., DeLao T., Bray P.F., and Kleiman N.S. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 47 (2006) 27-33
12. Matetzky S., Shenkman B., Guetta V., Shechter M., Bienart R., Goldenberg I., Novikov I., Pres H., Savion N., Varon D., and Hod H. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109 (2004) 3171-3175
13. Gurbel P.A., Bliden K.P., Samara W., Yoho J.A., Hayes K., Fissha M.Z., and Tantry U.S. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 46 (2005) 1827-1832
14. Barragan P., Bouvier J.L., Roquebert P.O., Macaluso G., Commeau P., Comet B., Lafont A., Camoin L., Walter U., and Eigenthaler M. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59 (2003) 295-302
15. Wenaweser P., Dorffler-Melly J., Imboden K., Windecker S., Togni M., Meier B., Haeberli A., and Hess O.M. Stent thrombosis is associated with an impaired response to antiplatelet therapy. J Am Coll Cardiol 45 (2005) 1748-1752
16. Joner M., Finn A.V., Farb A., Mont E.K., Kolodgie F.D., Ladich E., Kutys R., Skorija K., Gold H.K., and Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48 (2006) 193-202
17. Cutlip D.E., Windecker S., Mehran R., Boam A., Cohen D.J., van Es G.A., Steg P.G., Morel M.A., Mauri L., Vranckx P., McFadden E., Lansky A., Hamon M., Krucoff M.W., and Serruys P.W. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 115 (2007) 2344-2351
18. VerifyNow® Aspirin Assay Product Insert. San Diego, CA: Accumetrics, revised 9/18/07. Accessed from: http://accumetrics.com/products/VerifyNow/docs/VerifyNow_Aspirin_Instructions.pdf. Accessed August 1, 2008.
19. Paniccia R., Antonucci E., Gori A.M., Marcucci R., Giglioli C., Antoniucci D., Gensini G.F., Abbate R., and Prisco D. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 5 (2007) 1839-1847
20. Blindt R., Stellbrink K., de Taeye A., Muller R., Kiefer P., Yagmur E., Weber C., Kelm M., and Hoffmann R. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 98 (2007) 1329-1334
21. Buonamici P., Marcucci R., Migliorini A., Gensini G.F., Santini A., Paniccia R., Moschi G., Gori A.M., Abbate R., and Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 49 (2007) 2312-2317
22. Morel O., Viellard C., Faure A., Jesel L., Ohlmann P., Desprez D., Chauvin M., Roul G., Grunebaum L., and Bareiss P. [Platelet responsiveness to clopidogrel in patients with coronary syndrome: comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation]. Ann Cardiol Angeiol 56 (2007) 21-29
23. von Beckerath N., Pogatsa-Murray G., Wieczorek A., Sibbing D., Schomig A., and Kastrati A. Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb Haemost 95 (2006) 910-911
24. Aleil B., Ravanat C., Cazenave J.P., Rochoux G., Heitz A., and Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 3 (2005) 85-92
25. Airoldi F., Colombo A., Morici N., Latib A., Cosgrave J., Buellesfeld L., Bonizzoni E., Carlino M., Gerckens U., Godino C., Melzi G., Michev I., Montorfano M., Sangiorgi G.M., Qasim A., Chieffo A., Briguori C., and Grube E. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 116 (2007) 745-754
26. Price M.J., Endemann S., Gollapudi R.R., Valencia R., Stinis C.T., Levisay J.P., Ernst A., Sawhney N.S., Schatz R.A., and Teirstein P.S. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29 (2008) 992-1000
27. Bonello L., Camoin-Jau L., Arques S., Boyer C., Panagides D., Wittenberg O., Simeoni M.C., Barragan P., Dignat-George F., and Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51 (2008) 1404-1411
28. GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact on Thrombosis and Safety. Clinicaltrials.gov. http://clinicaltrials.gov/ct2/show/NCT00645918 Accessed August 1, 2008
29. Gurbel P.A., and Bliden K.P. Durability of platelet inhibition by clopidogrel. Am J Cardiol 91 (2003) 1123-1125
30. Lev E.I., Alviar C.L., Arikan M.E., Dave B.P., Granada J.F., DeLao T., Tellez A., Maresh K., and Kleiman N.S. Platelet reactivity in patients with subacute stent thrombosis compared with non-stent-related acute myocardial infarction. Am Heart J 153 (2007) e1-e6